<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981044</url>
  </required_header>
  <id_info>
    <org_study_id>SURE-007</org_study_id>
    <nct_id>NCT01981044</nct_id>
  </id_info>
  <brief_title>A SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sofregen Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sofregen Medical, Inc.</source>
  <brief_summary>
    <textblock>
      Prospective, multi center, single arm, clinical study to obtain clinical experience with the
      use of SERI® Surgical Scaffold for soft tissue support in ventral hernia repair.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hernia recurrence</measure>
    <time_frame>24 months postoperatively</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Ventral Hernia Repair</condition>
  <arm_group>
    <arm_group_label>SERI® Surgical Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silk surgical mesh</intervention_name>
    <description>A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair</description>
    <arm_group_label>SERI® Surgical Scaffold</arm_group_label>
    <other_name>SERI® Surgical Scaffold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The following are requirements for entry into the study. The subject MUST:

        1. Be ≥ 18 years of age

        2. Be diagnosed with a ventral hernia as defined as:

          1. Midline Ventral Hernia AND

          2. Defect(s) MUST meet the following criteria:

               -  contained within an anatomical area of ≤ 150 cm2

               -  not be longer than 8cm in any direction

               -  size must have a total sum ≤ 64 cm2

          3. Be eligible for retro-rectus placement of SERI

          4. Have a BMI &lt; 40

        Exclusion Criteria:

        The following are criteria for exclusion from participating in the study. The subject must

        NOT:

          1. Be &gt; 70 years of age

          2. Have prior occurrence of ventral hernia or parastomal hernia

          3. Have a presence of a stoma or have a perforated bowel

          4. Have any documented disease which is clinically known to impact wound healing,
             including Chronic Obstructive Pulmonary Disease (COPD), and Congestive Heart Failure
             (CHF), with the exception of controlled diabetes

          5. Have documented history of diabetes with an A1C of ≥ 8 at time of pre-operative visit

          6. Have documented autoimmune disease, an immune deficiency, or be on immunosuppressive
             drugs with the exception of steroids for:

        1. prophylactic one-time-use administered peri-operatively

        2. inhaled general use

        3. topical administration

        7. Have documented collagen-vascular, connective tissue, bleeding disorders and/or on
        anticoagulation therapy, with the exception of baby aspirin for one week prior to SERI
        placement

        8. Have documented cancer &lt; 6 months prior to surgery or chemotherapy treatment &lt; 6 months
        prior to surgery

        9. Have documented history of abdominal radiation therapy or is expected to have abdominal
        radiation therapy during the conduct of this study

        10. Have documented history of liver disease and/or renal failure requiring dialysis

        11. Have documented history of a previous wound infection at the surgical site or have an
        active infection at the time of surgery

        12. Have had prior surgery with synthetic and/or biologic mesh in the abdominal, chest or
        pelvic area

        13. Have documented allergy to silk

        14. Have documented UTI at the time of surgery

        15. Have smoked within 6 weeks of surgery and have a positive nicotine test at time of
        preoperative visit

        16. Have a concurrent procedure intra-operatively (with the exception of lysis of abdominal
        adhesions)

        17. Require intra-peritoneal or bridging placement of the soft tissue support device or
        require component separation at time of surgery

        18. Have surgical circumstances that are contraindicated for use of SERI™ Surgical Scaffold
        per the supplied package insert

        19. Have a concomitant unrelated condition of abdominal/chest wall/skin that would require
        a surgical intervention during the follow-up period

        20. Have documented alcohol and/or substance abuse problem at time of pre-operative visit

        21. Be pregnant, lactating, or if of childbearing potential, be unwilling to use
        contraceptive methods and avoid pregnancy throughout the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>November 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

